ReviewJournal of clinical medicine2020
Novel Evidence of Acute Kidney Injury in COVID-19.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Impact of prior bariatric surgery on risk and severity of COVID-19 infection: A meta-analysis of observational studies.Obesity research & clinical practicePooled it
- Clinical characteristics and mortality outcomes of acute kidney injury following COVID-19 infection in patients with chronic kidney disease at different stages.BMC infectious diseases · 2025Article
- Potential Alternative Receptors for SARS-CoV-2-Induced Kidney Damage: TLR-4, KIM-1/TIM-1, and CD147.Frontiers in bioscience (Landmark edition) · 2024Review
- Pathophysiological, immunological, and inflammatory features of long COVID.Frontiers in immunology · 2024Review
- Article
- Acute kidney injury among hospitalised patients who died due to COVID-19 in the Eastern Cape, South Africa.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2023Article
- Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center.Pathology oncology research : POR · 2023Article
- Targeting ACE2 as a potential prophylactic strategy against COVID-19-induced exacerbation of chronic kidney disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
- The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.International journal of molecular sciences · 2022Review
- The Role of Vitamin D in SARS-CoV-2 Infection and Acute Kidney Injury.International journal of molecular sciences · 2022Review
- Adamalysins in COVID-19 - Potential mechanisms behind exacerbating the disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area.Cancers · 2022Article
- Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service.Biomolecules · 2022Article
- eNAMPT Neutralization Preserves Lung Fluid Balance and Reduces Acute Renal Injury in Porcine Sepsis/VILI-Induced Inflammatory Lung Injury.Frontiers in physiology · 2022Article
- Acute Kidney Injury among Hospital-Admitted COVID-19 Patients: A Study from Jordan.International journal of general medicine · 2022Article
- Excess Body Mass-A Factor Leading to the Deterioration of COVID-19 and Its Complications-A Narrative Review.Viruses · 2021Review
- Role of microRNAs in COVID-19 with implications for therapeutics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- COVID-19-induced acute kidney injury in critically ill patients: epidemiology, risk factors, and outcome.Acute and critical care · 2021Article
- ADAMs family in kidney physiology and pathology.EBioMedicine · 2021Review
- Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus 2019 (COVID-19) pandemic has caused a huge impact on health and economic issues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes cellular damage by entry mediated by the angiotensin-converting enzyme 2 of the host cells and its conjugation with spike proteins of SARS-CoV-2. Beyond airway infection and acute respiratory distress syndrome, acute kidney injury is common in SARS-CoV-2-associated infection, and acute kidney injury (AKI) is predictive to multiorgan dysfunction in SARS-CoV-2 infection. Beyond the cytokine storm and hemodynamic instability, SARS-CoV-2 might directly induce kidney injury and cause histopathologic characteristics, including acute tubular necrosis, podocytopathy and microangiopathy. The expression of apparatus mediating SARS-CoV-2 entry, including angiotensin-converting enzyme 2, transmembrane protease serine 2 (TMPRSS2) and a disintegrin and metalloprotease 17 (ADAM17), within the renal tubular cells is highly associated with acute kidney injury mediated by SARS-CoV-2. Both entry from the luminal and basolateral sides of the renal tubular cells are the possible routes for COVID-19, and the microthrombi associated with severe sepsis and the dysregulated renin-angiotensin-aldosterone system worsen further renal injury in SARS-CoV-2-associated AKI. In the podocytes of the glomerulus, injured podocyte expressed CD147, which mediated the entry of SARS-CoV-2 and worsen further foot process effacement, which would worsen proteinuria, and the chronic hazard induced by SARS-CoV-2-mediated kidney injury is still unknown. Therefore, the aim of the review is to summarize current evidence on SARS-CoV-2-associated AKI and the possible pathogenesis directly by SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.